According to Fortune Business Insights, the global colorectal cancer screening market size was valued at USD 18.62 billion in 2025 and is projected to grow from USD 19.42 billion in 2026 to USD 27.69 billion by 2034, exhibiting a CAGR of 4.50% during the forecast period. North America dominated the colorectal cancer screening market with a market share of 65.04% in 2025.
The growing prevalence of colorectal cancer, increasing awareness of early disease detection, and rising adoption of advanced screening technologies are supporting market expansion. Colorectal cancer screening involves medical tests and diagnostic procedures used to identify precancerous polyps or cancer at an early stage. These screening methods include stool-based tests, colonoscopy, flexible sigmoidoscopy, and advanced molecular diagnostic techniques. Early detection enables timely medical intervention and improves treatment outcomes.
Rising Prevalence of Colorectal Cancer
The increasing incidence of colorectal cancer worldwide is creating a greater need for effective screening solutions. Lifestyle changes, unhealthy dietary habits, physical inactivity, obesity, and an aging population are contributing to the growing disease burden. Consequently, healthcare providers are emphasizing regular screening programs to identify abnormalities and reduce cancer-related mortality.
Growing Awareness of Early Cancer Detection
Increasing awareness of preventive healthcare and early cancer diagnosis is encouraging individuals to undergo routine colorectal cancer screening. Government initiatives, public health campaigns, and recommendations from healthcare organizations are supporting screening participation, particularly among high-risk populations and eligible age groups.
Advancements in Screening and Diagnostic Technologies
Technological developments in molecular diagnostics, genetic testing, and stool-based screening methods are improving colorectal cancer detection. Non-invasive screening options are gaining attention because they offer convenient testing alternatives and may encourage greater participation among individuals who are reluctant to undergo invasive procedures.
Increasing Adoption of Non-Invasive Screening Tests
Non-invasive screening methods, including fecal immunochemical tests (FIT) and stool-based DNA tests, are gaining popularity. These solutions offer convenient sample collection and can help identify potential signs of colorectal cancer without requiring an immediate invasive procedure. Their growing availability is supporting broader screening adoption.
Growing Use of Advanced Molecular Diagnostics
Molecular diagnostic technologies are becoming increasingly important in colorectal cancer screening. These methods analyze genetic and molecular biomarkers to identify cancer-associated changes. Continued research into blood-based and stool-based biomarkers is expected to create opportunities for more accessible screening solutions.
Expansion of Organized Screening Programs
Healthcare authorities and medical institutions are strengthening colorectal cancer screening initiatives to improve early diagnosis rates. Organized screening programs, awareness campaigns, and improved access to diagnostic services are encouraging more individuals to participate in preventive healthcare.
North America dominated the global colorectal cancer screening market with a share of 65.04% in 2025. The region's leadership is supported by advanced healthcare infrastructure, increasing awareness of early cancer detection, established screening guidelines, and the availability of advanced diagnostic technologies.
The presence of leading diagnostic companies, growing adoption of stool-based screening tests, and supportive healthcare reimbursement frameworks are further strengthening the regional market. Additionally, government-backed cancer prevention initiatives and increasing investments in diagnostic research are contributing to market development.